All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Hematologists and Patients Come Together for Patient-Focused GVHD Discussions

February 17th 2024

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

FDA Approves Osimertinib Plus Chemo for EGFR-Mutated NSCLC

February 16th 2024

The FDA has approved osimertinib (Tagrisso) plus chemotherapy for use in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

FDA Approves Lifileucel for Unresectable or Metastatic Melanoma

February 16th 2024

The FDA has approved lifileucel suspension (Amtagvi) for adult patients with unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor.

Enfortumab Vedotin Plus Pembrolizumab Receives Priority Review in Japan for First-Line Urothelial Carcinoma

February 16th 2024

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma

February 16th 2024

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State Offering Novel Form of Liver Cancer Treatment

February 16th 2024

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health will offer hepatic artery infusion therapy for patients with liver tumors.

Jagsi Holds a Magnifying Glass to Radiation Oncology: Uncovering Key Disparities and When to Omit Radiation in Breast Cancer

February 16th 2024

Investigating when radiation therapy can be appropriately omitted and striving to uncover disparities are areas of focus in the field of radiation oncology.

Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT

February 16th 2024

R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.

FDA Approves AI-Powered Detection Device for Skin Cancers

February 16th 2024

The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .

Insights Into Pediatric Oncology on Childhood Cancer Day: Advances, Challenges, and Survivorship

February 15th 2024

Burton Eliot Appel, MD, discusses the landscape of pediatric oncology on International Childhood Cancer Day.

FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations

February 15th 2024

The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

February 15th 2024

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

Breaking Boundaries: Advancements and Challenges in Treatment with ADCs in NSCLC

February 15th 2024

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Enfortumab Vedotin/Pembrolizumab Signals Shift in Urothelial Carcinoma Treatment Paradigm

February 15th 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

Florida Cancer Specialists & Research Institute Welcomes Gynecologic Oncologist Bradley Monk, MD, FACOG, FACS To Lead Late-Phase Clinical Research Program

February 15th 2024

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD, FACOG, FACS has joined the statewide practice.

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

February 15th 2024

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Are Higher Standards for Expedited FDA Approvals Needed?

February 15th 2024

Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.

Updates to MDS Classification Complicate Yet Better Inform Treatment Navigation in MDS

February 15th 2024

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

BLA Resubmitted to FDA for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-cell Lymphoma

February 14th 2024

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

Unlocking the Potential: The Evolution of ADCs in HER2+ NSCLC

February 14th 2024

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.